Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorder and Membrane Asymmetry Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP8A2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Prep | ATP8A2 Extracellular Loop (ECL) Peptides & Mutants. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ATP8A2 Products |
| Gene Delivery | ATP8A2 Lentivirus Premade Particles. Full-length ORF with CDC50A co-expression for functional flippase assays. Sequence Verified. | View ATP8A2 Products |
| Disease Model | ATP8A2 Mutant Variants (CAMRQ-associated). Gln932Ter, Arg867Gln, Cys199Phe recombinant variants. High Purity (>95%). | View ATP8A2 Products |
| Functional Partner | CDC50A (TMEM30A) Co-expression System. Required beta-subunit for ATP8A2 plasma membrane targeting and activity. | View CDC50A Products |
| Benchmark Ab | Anti-ATP8A2 (Research Grade). Recombinant positive control for western blot and FACS. | View ATP8A2 Products |
| Validator | ATP8A2 siRNA Set. For knockdown verification and specificity controls. Sequence Verified. | View ATP8A2 Products |
| Related Flippase | ATP8B1 (FIC1). Bile salt export regulation, cholestatic disease research. Sequence Verified. | View ATP8B1 Products |
| Homolog Counter-screen | ATP8A1. Closely related homolog for selectivity screening and safety profiling. | View ATP8A1 Products |
| Lipid Transporter | ABCA1. Cholesterol efflux partner, membrane asymmetry pathway. | View ABCA1 Products |
Critical Assay Challenges vs. TarMart Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Topology Preservation (Multi-pass TM) | Lentivirus-Mediated Stable Cell Lines preserving native transmembrane conformation; HEK293 Expressed for proper glycosylation. |
| Phospholipid Flippase Activity Measurement | Full-Length ATP8A2 + CDC50A Co-expression System; NBD-PS/PE uptake assay compatible. |
| Disease Mutation Validation | Cerebellar Ataxia CAMRQ-associated mutants (Q932X, R867Q, C199F) available as recombinant proteins; Endotoxin <1EU/ug. |
| Subunit Dependency (CDC50A) | CDC50A (TMEM30A) accessory protein available for heterodimeric complex formation validation. Tight co-expression ensures proper membrane targeting. |
| Lack of Reliable Native Controls | Research grade benchmark antibodies and validated siRNA for baseline validation and specificity checks. |
| Distinguishing Off-Target Activity | Homolog counter-screening panel including ATP8A1, ATP8B1 and ABCA1 for selectivity profiling. |
Live ATP8A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Membrane Biology Research
- ➤ Cerebellar Ataxia & CAMRQ Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The ATP8A2 therapeutic landscape represents a unique convergence of rare monogenic disease therapy and emerging immuno-oncology applications. As the primary phosphatidylserine flippase responsible for maintaining membrane asymmetry in neuronal tissues, ATP8A2 loss-of-function mutations cause Cerebellar Ataxia, Mental Retardation, and Disequilibrium Syndrome (CAMRQ4). The race for ATP8A2 therapeutics is intensifying, with major players shifting focus from traditional enzyme replacement to AAV-mediated gene therapy, small molecule chaperones, and targeted protein degradation. As first-generation gene therapies reach preclinical stages for CAMRQ, the next wave of R&D is targeting lipid asymmetry modulation in cancer immunotherapy, neurodegenerative disorders, and retinal degeneration. Key clinical challenges include efficient CNS delivery via AAV, restoration of flippase activity in patient-derived cells, and selective targeting of ATP8A2 without cross-reactivity with other P4-ATPases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | Academic Consortia, Rare Disease Biotechs | CAMRQ4, Retinal Degeneration | Functional Rescue Assay (Need Disease-mutant ATP8A2 Lentivirus for cellular uptake studies) |
| Small Molecule Chaperones | Neuroscience Biotechs, Specialty Pharma | Neurodegeneration (CAMRQ, protein misfolding) | Thermal Stability & Flippase Activity Assay (Need High-purity WT vs Mutant ATP8A2 proteins; Stable Cell Lines co-expressing ATP8A2/CDC50A) |
| Lipid Modulators | Cancer Immunology Labs | Solid Tumors (PS Externalization) | Flippase Activity Assay (Need Active ATP8A2-CDC50A Complex in Native Membrane) |
| Protein Replacement | Enzyme Therapy Developers | Neurodegeneration | Blood-Brain Barrier Penetration Assay (Need Species-cross-reactive ATP8A2 variants) |
| Targeted Protein Degraders | Early-stage Innovators | Proteotoxicity Models | Selectivity Assay (Need Wild Type vs Mutant Plasmids; Homolog panel for off-target profiling) |
Note: ATP8A2 is a P4-type ATPase requiring obligate interaction with CDC50A (TMEM30A) for plasma membrane localization and phospholipid transport activity. Cell-based assays utilizing Lentivirus-delivered stable expression systems are essential for accurate functional characterization.
Related Targets for Cross-sell
- CDC50A (TMEM30A): Obligate beta-subunit; any ATP8A2 functional study must include CDC50A co-expression. Strong cross-sell for complex assembly validation.
- ATP8A1: Closely related CNS homolog; essential for selectivity counter-screening to avoid off-target toxicity.
- ATP8B1 (FIC1): Bile salt flippase, useful for comparative P4-ATPase family studies.
- ABCA1: Cholesterol efflux transporter cooperating with ATP8A2 in membrane asymmetry maintenance; relevant for Alzheimer's and cardiovascular research.
- TIM-4 / BAI1: PS receptors recognizing externalized phosphatidylserine ('Eat-Me' signal); ATP8A2 activity reduction increases PS exposure, enhancing phagocytosis. Combine ATP8A2 modulators with TIM-4 reporter cells for immuno-oncology applications.